Cargando…

Effects of Trial Population Selection on Quality of Life and Healthcare Decision-Making: A Systematic Review and Example in the Treatment of Hepatocellular Carcinoma with Radioembolization

BACKGROUND AND AIMS: Quality of life is among the most important considerations in the treatment of hepatocellular carcinoma (HCC), arguably second only to overall survival. Measuring and modeling patient quality of life is also crucial in the evaluation of the cost-effectiveness of health intervent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pollock, Richard F, Colaone, Fabien, Shergill, Suki, Brennan, Victoria K, Agirrezabal, Ion
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473933/ https://www.ncbi.nlm.nih.gov/pubmed/34588788 http://dx.doi.org/10.2147/CEOR.S319857

Ejemplares similares

Transarterial Radioembolization Versus Atezolizumab–Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life
por: Agirrezabal, Ion, et al.
Publicado: (2022)

Advances in Delivery of Selective Internal Radiation Therapy (SIRT): Economic and Logistical Effects of Same-Stay Work-Up and Procedure in the Treatment of Unresectable Liver Tumors in England
por: Pollock, Richard F., et al.
Publicado: (2022)

Systematic review and network meta-analyses of third-line treatments for metastatic colorectal cancer
por: Walter, Thomas, et al.
Publicado: (2020)

Radioembolization for the treatment of hepatocellular carcinoma
por: Kim, Hyo-Cheol
Publicado: (2017)

Optimization of the Clinical Effectiveness of Radioembolization in Hepatocellular Carcinoma with Dosimetry and Patient-Selection Criteria
por: d’Abadie, Philippe, et al.
Publicado: (2022)

Radioembolization for Hepatocellular Carcinoma using TheraSphere(®)
por: Ali, Safiyya Mohamed
Publicado: (2011)

Transarterial radioembolization for hepatocellular carcinoma: a review
por: Sacco, Rodolfo, et al.
Publicado: (2016)

Radioembolization Followed by Transarterial Chemoembolization in Hepatocellular Carcinoma
por: Vardar, Baran U, et al.
Publicado: (2022)

Yttrium-90 radioembolization for advanced inoperable hepatocellular carcinoma
por: Lee, Victor Ho-Fun, et al.
Publicado: (2015)

Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma
por: Kallini, Joseph Ralph, et al.
Publicado: (2016)

History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma
por: Saini, Aman, et al.
Publicado: (2019)

Yttrium-90 Radioembolization as the Major Treatment of Hepatocellular Carcinoma
por: Yu, Chun-Yen, et al.
Publicado: (2023)

Radioembolization for hepatocellular carcinoma: what clinicians need to know
por: Choi, Jin Woo, et al.
Publicado: (2022)

Transarterial Radioembolization for Unresectable Hepatocellular Carcinoma: Real-Life Efficacy and Safety Analysis of Korean Patients
por: Yim, Sun Young, et al.
Publicado: (2022)

Beyond Hepatocellular Carcinoma and Colorectal Metastasis: The Expanding Applications of Radioembolization
por: Zurkiya, Omar, et al.
Publicado: (2014)

Prognostic ability of inflammation-based markers in radioembolization for hepatocellular carcinoma
por: Yoneoka, Grant, et al.
Publicado: (2020)

The physics of radioembolization
por: Bastiaannet, Remco, et al.
Publicado: (2018)

LiMAx Prior to Radioembolization for Hepatocellular Carcinoma as an Additional Tool for Patient Selection in Patients with Liver Cirrhosis
por: Leyh, Catherine, et al.
Publicado: (2022)

Importance of Shared Decision-Making for Vulnerable Populations: Examples from Postmastectomy Breast Reconstruction
por: Grabinski, Victoria F., et al.
Publicado: (2018)

Transarterial Radioembolization for the Treatment of Advanced Hepatocellular Carcinoma Invading the Right Atrium
por: Girardet, Raphaël, et al.
Publicado: (2020)

Highlighting Survival with Yttrium-90 Radioembolization Therapy in Unresectable Hepatocellular Carcinoma
por: Nabrinsky, Edward, et al.
Publicado: (2020)

Preliminary evaluation of alpha-emitting radioembolization in animal models of hepatocellular carcinoma
por: Du, Yong, et al.
Publicado: (2022)

Long-term outcome analysis of Y90 radioembolization in hepatocellular carcinoma
por: Lee, Hannah M., et al.
Publicado: (2023)

Selecting the Appropriate Downstaging and Bridging Therapies for Hepatocellular Carcinoma: What Is the Role of Transarterial Radioembolization? A Pooled Analysis
por: Lopez-Lopez, Victor, et al.
Publicado: (2023)

Comparison between Y90 Radioembolization Plus Sorafenib and Y90 Radioembolization alone in the Treatment of Hepatocellular Carcinoma: A Propensity Score Analysis
por: Facciorusso, Antonio, et al.
Publicado: (2020)

A decision tool to help researchers make decisions about including systematic reviews in overviews of reviews of healthcare interventions
por: Pollock, Michelle, et al.
Publicado: (2019)

Bilobar Radioembolization Carries the Risk of Radioembolization-Induced Liver Disease in the Treatment of Advanced Hepatocellular Carcinoma: Safety and Efficacy Comparison to Systemic Therapy with Atezolizumab/Bevacizumab
por: Jeschke, Matthias, et al.
Publicado: (2023)

Yttrium-90 radioembolization for unresectable hepatocellular carcinoma: predictive modeling strategies to anticipate tumor response and improve patient selection
por: Lüdemann, Willie, et al.
Publicado: (2022)

Sequential tumor-directed and lobar radioembolization before major hepatectomy for hepatocellular carcinoma
por: Vouche, Michael, et al.
Publicado: (2017)

Yttrium-90 radioembolization of unresectable hepatocellular carcinoma – a single center experience
por: Meyer, Carsten, et al.
Publicado: (2017)

Factors associated with contralateral liver hypertrophy after unilateral radioembolization for hepatocellular carcinoma
por: Goebel, Juliane, et al.
Publicado: (2017)

Extrahepatic transarterial radioembolization to treat fibrolamellar hepatocellular carcinoma: A case report
por: Ljuboja, Damir, et al.
Publicado: (2020)

Predictors of Complete Response in Patients with Hepatocellular Carcinoma Treated with Trans-Arterial Radioembolization
por: Kim, Yuna, et al.
Publicado: (2021)

Predictors of Successful Yttrium-90 Radioembolization Bridging or Downstaging in Patients with Hepatocellular Carcinoma
por: Villalobos, Alexander, et al.
Publicado: (2021)

Radiometal-Labeled Chitosan Microspheres as Transarterial Radioembolization Agents against Hepatocellular Carcinoma
por: Chan, Hui-Wen, et al.
Publicado: (2022)

Evaluation of staging systems to predict prognosis in hepatocellular carcinoma patients treated with radioembolization
por: Meram, Ece, et al.
Publicado: (2022)

Bridging treatment prior to liver transplantation for hepatocellular carcinoma: radioembolization or transarterial chemoembolization?
por: Benkö, Tamás, et al.
Publicado: (2022)

Yttrium-90 transarterial radioembolization and capecitabine in hepatocellular carcinoma with portal vein involvement
por: Şener, Nur, et al.
Publicado: (2023)

On the ethics of algorithmic decision-making in healthcare
por: Grote, Thomas, et al.
Publicado: (2020)

Representation in participatory healthcare decision‐making
por: Moore, Emma L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_78u0e7jac4lvduppu32actuu14